Showing results (1271-1280 of 5,347) with videos related to

Sort By:
Pageof 535
Japanese Journal of Clinical Oncology|August 30, 2023
The association of miR-204 and mir-483 5p expression with clinicopathological features of Wilms tumor: Could this provide foresight?Aylin Orgen Calli, Gizem Issin, Ismail Yilmaz, et al.
Japanese Journal of Clinical Oncology|April 13, 2026
Non-surgical definitive treatment and geriatric assessment in older patients with locally advanced head and neck cancerKoichi Yasuda, Yoshitaka Honma, Yuri Ueda, et al.
Japanese Journal of Clinical Oncology|March 20, 2026
Trends in survival for patients with esophageal cancer in Japan, 2000-14 (CONCORD-3)Tomohiro Matsuda, Veronica Di Carlo, Melissa Matz, et al.
Japanese Journal of Clinical Oncology|March 20, 2026
Trends in net survival for prostate cancer in Japan, 2000-14 (CONCORD-3)Rina Tanaka, Melissa Matz, Hiromi Sugiyama, et al.
Japanese Journal of Clinical Oncology|April 13, 2026
Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study)Yusuke Sano, Masato Ozaka, Shuichi Aoki, et al.
Japanese Journal of Clinical Oncology|April 17, 2026
Global evidence and clinical implications of spontaneous tumor lysis syndrome in older adults with solid tumors: a systematic review of reported casesSamuel M Pettit, Na Liu
Japanese Journal of Clinical Oncology|April 14, 2026
Hypofractionated radiotherapy across cancer sites: a narrative review of evidence and implementationMasahiro Inada, Takuya Uehara, Yukinori Matsuo
Japanese Journal of Clinical Oncology|April 30, 2026
Impact of treatment volume on outcomes for patients with penile cancer at relatively low-volume centers in JapanYoji Murakami, Takahiro Yamaguchi, Masato Goya, et al.
Japanese Journal of Clinical Oncology|April 13, 2026
Development of a visualization tool to estimate out-of-pocket costs for systemic cancer therapy in Japan and claims-based agreement evaluation: the VEST-Ca studyKazunori Honda, Kazuhiro Shimomura, Hiroya Taniguchi, et al.
Japanese Journal of Clinical Oncology|January 9, 2026
Pretreatment predictive factors for primary resistance to nivolumab plus ipilimumab in advanced renal cell carcinoma: a multicenter collaborative studyKimihiko Masui, Naoki Hayata, Toshinari Yamasaki, et al.
Pageof 535